Although significant progress in tumor therapy was achieved in the last two decades with numerous protein kinase inhibitors, relatively few of the tumor-relevant protein kinases have been exploited as targets in clinical therapy by selective inhibitors. This evidence concerns the gene WEE1 and neoplasm.